Bill Sponsor
House Bill 6062
116th Congress(2019-2020)
To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes.
Introduced
Introduced
Introduced in House on Mar 3, 2020
Overview
Text
Introduced
Mar 3, 2020
Latest Action
Mar 4, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
6062
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Illinois
Republican
Georgia
Democrat
New Jersey
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

This bill expands existing requirements relating to supply shortages of life-saving drugs to also apply to life-saving medical devices.

Generally, a manufacturer must (1) notify the Food and Drug Administration (FDA) of supply interruptions in certain circumstances, (2) provide for the expedited review of a new device that may mitigate the shortage, and (3) allow the FDA to authorize the importation of the device for emergency medical care.

Text (1)
March 3, 2020
Actions (3)
03/04/2020
Sponsor introductory remarks on measure. (CR H1476)
03/03/2020
Referred to the House Committee on Energy and Commerce.
03/03/2020
Introduced in House
Public Record
Record Updated
Feb 9, 2022 1:42:23 AM